Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
mental disorders | D001523 |
Brand Name | Status | Last Update |
---|---|---|
generic drug | unapproved drug other | 2019-05-07 |
ibuprofen | ANDA | 2014-12-05 |
memantine | ANDA | 2024-09-26 |
memantine and donepezil hydrochlorides | ANDA | 2025-01-01 |
memantine and donepezil hydrochlorides extended-release | ANDA | 2025-02-06 |
memantine hcl | ANDA | 2024-02-29 |
memantine hydrochloride | ANDA | 2025-02-04 |
memantine hydrochloride memantine hydrochloride | ANDA | 2021-12-22 |
namenda | New Drug Application | 2019-11-30 |
namenda namenda xr | New Drug Application | 2017-12-28 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
alzheimer disease | EFO_0000249 | D000544 | F03 |
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Donepezil Hydrochloride / Memantine Hydrochloride, Namzaric, Abbvie | |||
8058291 | 2029-12-05 | U-1641 | |
8039009 | 2029-03-24 | U-539, U-1641 | |
8168209 | 2025-11-22 | DP | |
8173708 | 2025-11-22 | U-1641 | |
8283379 | 2025-11-22 | U-1641 | |
8293794 | 2025-11-22 | DP | |
8329752 | 2025-11-22 | DP | |
8338485 | 2025-11-22 | DP | |
8338486 | 2025-11-22 | U-1641 | |
8362085 | 2025-11-22 | U-1641 | |
8580858 | 2025-11-22 | U-1641 | |
8598233 | 2025-11-22 | DP |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glaucoma | D005901 | EFO_0000516 | H40 | — | — | 2 | — | — | 2 |
Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | — | 2 | — | — | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | — | 1 |
Drug common name | Memantine |
INN | memantine |
Description | Memantine is a primary aliphatic amine that is the 3,5-dimethyl derivative of 1-aminoadamantane. A low to moderate affinity uncompetitive (open-channel); NMDA receptor antagonist which binds preferentially to the NMDA receptor-operated cation channels. It has a role as a dopaminergic agent, an antiparkinson drug, a NMDA receptor antagonist, a neuroprotective agent and an antidepressant. It is a member of adamantanes and a primary aliphatic amine. It is a conjugate base of a memantinium(1+). It derives from a hydride of an adamantane. |
Classification | Small molecule |
Drug class | antivirals/antiparkinsonians (adamantane derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CC12CC3CC(C)(C1)CC(N)(C3)C2 |
PDB | — |
CAS-ID | 19982-08-2 |
RxCUI | — |
ChEMBL ID | CHEMBL807 |
ChEBI ID | 64312 |
PubChem CID | 4054 |
DrugBank | DB01043 |
UNII ID | W8O17SJF3T (ChemIDplus, GSRS) |